drugset / Trial / NCT06710379
A Study of ADRX-0405 in Subjects With Select Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
The primary purpose of this study is to assess the safety, tolerability, and pharmacokinetics, and to identify the optimal dose of ADRX-0405 in patients with select advanced solid tumors.
Timeline
- Start
- 2024-12-30
- Primary completion
- 2026-07
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ADRX-0405 | Unknown | — | — |